AN2 Therapeutics Files S-3 for $300M Universal Shelf, $80M ATM, and Resale of 14M Shares

summarizeSummary

AN2 Therapeutics filed a new S-3 shelf registration for $300 million, including a new $80 million At-The-Market (ATM) offering and the registration of 14 million shares for resale by selling securityholders from a recent private placement. This represents a substantial potential dilution.

check_boxKey Events

• New Universal Shelf Registration

  The company filed a new S-3 registration statement for up to $300 million in various securities, replacing an expiring shelf from April 2023. This provides broad flexibility for future capital raises.

• Establishes $80M At-The-Market (ATM) Offering

  A sales agreement prospectus supplement details a new ATM program with Jefferies LLC, allowing the company to sell up to $80 million of common stock. This program was announced concurrently with an 8-K filing.

• Registers 14M Shares for Resale by Selling Securityholders

  The S-3 includes a resale prospectus supplement for 14,035,104 shares of common stock, comprising 8,245,611 issued shares and 5,789,493 shares from pre-funded warrants, all acquired in a private placement on March 8, 2026.

• Significant Potential Dilution

  The $80 million ATM offering alone represents a potential dilution of approximately 62.87% based on current outstanding shares (after the private placement), while the resale shares represent an additional potential dilution of approximately 33.86%.

auto_awesomeAnalysis

AN2 Therapeutics has filed a new universal shelf registration statement on Form S-3, replacing an expiring one from April 2023. This new filing registers up to $300 million in various securities, including common stock, preferred stock, debt, warrants, and units. Concurrently, the company is registering a new At-The-Market (ATM) equity offering program with Jefferies LLC, allowing it to sell up to $80 million of common stock from time to time. This $80 million ATM represents a substantial potential dilution, equivalent to approximately 73% of the company's current market capitalization. Additionally, the S-3 registers 14,035,104 shares for resale by selling securityholders, which were acquired in a private placement on March 8, 2026. This resale registration, following a recent private placement, adds further potential supply to the market. The combined potential dilution from these offerings is significant and could exert considerable downward pressure on the stock price.